USA - NASDAQ:ABEO - US00289Y2063 - Common Stock
Overall ABEO gets a fundamental rating of 3 out of 10. We evaluated ABEO against 534 industry peers in the Biotechnology industry. ABEO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ABEO is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 14310.5% | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.73 | ||
| Quick Ratio | 6.65 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.28
-0.26 (-4.69%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.14 | ||
| P/S | 676.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.66 | ||
| P/tB | 1.66 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 14310.5% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 172.41% | ||
| Cap/Sales | 1328% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.73 | ||
| Quick Ratio | 6.65 | ||
| Altman-Z | -2.14 |
ChartMill assigns a fundamental rating of 3 / 10 to ABEO.
ChartMill assigns a valuation rating of 3 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.
ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.